BRAF and melanoma: Suppression of B-Raf(V600E)-driven transformation by MEDICA [HOOC-C(CH3)2 -(CH2)12-C(CH3)2-COOH] was verified in a variety of colorectal (CRC) (HT29, RKO), melanoma (A375, UACC62) and papillary thyroid carcinoma (PTC) (BcPAP) cells, where B-Raf(V600E) serves as major oncogenic driver, and treatment with B-Raf(V600E) kinase inhibitors fails due to primary or acquired resistance.